HRH3 and Cognitive impairment: In line with the above view, Abbott has suggested a combinatorial treatment of cognitive disorders consisting of a nAChR ligand (either α4β2 or α7 subtype) and a H3R antagonist e.g., ABT-239 (Abbott laboratories, WO2009082698; 2009) which can also include psychostimulants (e.g., methylphenidate) or monoamine re-uptake inhibitors (e.g., atomoxetine) to achieve greater clinical efficacy (Lazewska and Kiec-Kononowicz, 2010).